ATE437943T1 - Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung. - Google Patents

Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.

Info

Publication number
ATE437943T1
ATE437943T1 AT97903998T AT97903998T ATE437943T1 AT E437943 T1 ATE437943 T1 AT E437943T1 AT 97903998 T AT97903998 T AT 97903998T AT 97903998 T AT97903998 T AT 97903998T AT E437943 T1 ATE437943 T1 AT E437943T1
Authority
AT
Austria
Prior art keywords
gene expression
recombinant gene
antigen
vectors
expression vectors
Prior art date
Application number
AT97903998T
Other languages
English (en)
Inventor
Dennis Carson
Eyal Raz
Mark Roman
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24375188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE437943(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE437943T1 publication Critical patent/ATE437943T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT97903998T 1996-01-30 1997-01-28 Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung. ATE437943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59355496A 1996-01-30 1996-01-30
PCT/US1997/001277 WO1997028259A1 (en) 1996-01-30 1997-01-28 Gene expression vectors which generate an antigen specific immune response and methods of using the same

Publications (1)

Publication Number Publication Date
ATE437943T1 true ATE437943T1 (de) 2009-08-15

Family

ID=24375188

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97903998T ATE437943T1 (de) 1996-01-30 1997-01-28 Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.

Country Status (7)

Country Link
US (1) US20030203861A1 (de)
EP (1) EP0879284B1 (de)
JP (1) JP4359654B2 (de)
AT (1) ATE437943T1 (de)
CA (1) CA2244946C (de)
DE (1) DE69739515D1 (de)
WO (1) WO1997028259A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
AU4992197A (en) 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
EP1005368B1 (de) * 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
KR20080009171A (ko) * 1997-08-13 2008-01-24 더 유에이비 리서치 파운데이션 유전자 벡터의 국소 적용에 의한 백신접종
WO1999011275A2 (en) * 1997-09-05 1999-03-11 The Regents Of The University Of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1674574A1 (de) * 1998-05-14 2006-06-28 Coley Pharmaceutical GmbH Verfahren zur Regulierung der Hematopoiese mit Hilfe von CpG Oligonukleotide
CA2328894A1 (en) 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP1176966B1 (de) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2001012223A2 (en) 1999-08-19 2001-02-22 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
CA2721011A1 (en) * 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2001231245A1 (en) 2000-01-31 2001-08-07 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
DE60142410D1 (de) 2000-12-27 2010-07-29 Dynavax Tech Corp Immunomodulatorische polynukleotide und verfahren zur deren verwendung
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US20030199466A1 (en) 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
CA2456328C (en) 2001-08-07 2015-05-26 Dynavax Technologies Corporation Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
CA2494911A1 (en) 2002-08-12 2004-02-19 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
KR20050089799A (ko) 2002-10-29 2005-09-08 콜리 파마슈티칼 그룹, 리미티드 Ｃ형 간염 바이러스 감염의 치료에 있어 ＣｐＧ올리고뉴클레오티드의 용도
CA2504493C (en) 2002-11-01 2015-12-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
AU2003302743B2 (en) 2002-12-23 2008-09-04 Dynavax Technologies Corporation Branched immunomodulatory compounds and methods of using the same
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
DE60329223D1 (de) 2002-12-23 2009-10-22 Dynavax Tech Corp Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
AU2004223736B2 (en) 2003-03-26 2010-05-27 Cytos Biotechnology Ag Melan-A peptide analogue-virus-like-particle conjugates
JP2008531722A (ja) 2005-03-04 2008-08-14 ダイナバックス テクノロジーズ コーポレイション 構造的に安定なコンジュゲート分子を含む組成物
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
PL2269622T3 (pl) 2005-07-01 2014-05-30 Index Pharmaceuticals Ab Sposób do modulowania wrażliwości na steroidy
PL2179737T3 (pl) 2005-07-01 2014-01-31 Index Pharmaceuticals Ab Sposób do modulowania wrażliwości na steroidy
JP2009513629A (ja) 2005-10-28 2009-04-02 インデックス・ファーマシューティカルズ・アクチエボラーグ 炎症性疾患を予防、処置、および／または緩和する組成物および方法
JP5484732B2 (ja) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子
KR101065760B1 (ko) * 2006-05-31 2011-09-19 오사카 유니버시티 면역자극 올리고뉴클레오티드 및 그 의약 용도
WO2007144150A1 (en) 2006-06-12 2007-12-21 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
WO2008073661A2 (en) 2006-11-09 2008-06-19 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
US8815817B2 (en) 2008-05-15 2014-08-26 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
CN105056229A (zh) 2009-01-05 2015-11-18 埃皮托吉尼西斯股份有限公司 佐剂组合物及使用方法
KR20110117654A (ko) * 2009-01-13 2011-10-27 트랜스진 에스.에이. 면역 자극에 있어서의 사카로미세스 세레비지아에 미토콘드리아 핵산 분획물의 용도
EP3216789A1 (de) 2010-02-12 2017-09-13 Chimerix, Inc. Verfahren zur behandlung von vireninfektionen
CA2792258A1 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
EP2596806A1 (de) 2011-11-25 2013-05-29 Index Pharmaceuticals AB Verfahren zur Vorbeugung einer Dickdarmresektion
US9717657B2 (en) 2012-10-24 2017-08-01 Amy Dukoff Composition and method of using medicament for endodontic irrigation, stem cell preparations and tissue regeneration
AU2014236340B2 (en) 2013-03-14 2019-01-17 Massachusetts Institute Of Technology Nanoparticle-based compositions
AU2016271018A1 (en) 2015-05-29 2017-11-30 Dynavax Technologies Corporation Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
WO2023081486A1 (en) 2021-11-08 2023-05-11 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3596660A (en) * 1969-05-12 1971-08-03 Illinois Tool Works Injection device
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5985847A (en) * 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US20030109469A1 (en) * 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT772619E (pt) * 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
AU4992197A (en) * 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) * 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
ATE370740T1 (de) * 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
WO1999011275A2 (en) * 1997-09-05 1999-03-11 The Regents Of The University Of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
DE69935507T2 (de) * 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1674574A1 (de) * 1998-05-14 2006-06-28 Coley Pharmaceutical GmbH Verfahren zur Regulierung der Hematopoiese mit Hilfe von CpG Oligonukleotide
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6887464B1 (en) * 1999-02-02 2005-05-03 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
AU2001231245A1 (en) * 2000-01-31 2001-08-07 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
AU4175101A (en) * 2000-02-23 2001-09-03 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
WO2001097843A2 (en) * 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
WO2002028426A1 (en) * 2000-10-02 2002-04-11 Glaxosmithkline Biologicals S.A. Split enveloped virus preparation
AU2001297693A1 (en) * 2000-12-08 2002-09-12 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US20030162734A1 (en) * 2001-06-28 2003-08-28 Miller Carol A. Modulation of DENN-MADD expression and interactions for treating neurological disorders
CA2388049A1 (en) * 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
ATE318916T1 (de) * 2002-09-01 2006-03-15 Univ Washington Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen
GB0304424D0 (en) * 2003-02-26 2003-04-02 Glaxosmithkline Biolog Sa Novel compounds
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
WO2007026190A2 (en) * 2004-07-18 2007-03-08 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US8110196B2 (en) * 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination

Also Published As

Publication number Publication date
DE69739515D1 (de) 2009-09-10
CA2244946C (en) 2010-04-13
EP0879284B1 (de) 2009-07-29
WO1997028259A1 (en) 1997-08-07
EP0879284A4 (de) 2002-05-29
JP2000503853A (ja) 2000-04-04
JP4359654B2 (ja) 2009-11-04
US20030203861A1 (en) 2003-10-30
EP0879284A1 (de) 1998-11-25
CA2244946A1 (en) 1997-08-07

Similar Documents

Publication Publication Date Title
ATE437943T1 (de) Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
KR102858623B1 (ko) 신규 인공 핵산 분자
Ulmer et al. DNA vaccines
EP3452493B1 (de) Nukleinsäuremoleküle und verwendungen davon
JP5931120B2 (ja) 哺乳動物において免疫を賦活する応答を提供または増強するための複合化された（ｍ）ＲＮＡと裸のｍＲＮＡとを含んでいる組成物、およびその使用
DE69838294D1 (de) Verfahren zur Herstellung von Nukleinsäurekonstrukten
WO2002061113A3 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
EA014757B1 (ru) Химерный аденовирусный вектор, иммуногенная композиция на его основе, способ индукции иммуного ответа с его помощью и выделенная нуклеиновая кислота
NO975730L (no) Metode for ökning av beskyttende immunresponser
Staib et al. Improved host range selection for recombinant modified vaccinia virus Ankara
CN105617373B (zh) 一种疫苗组合物及其制备方法和应用
Yamada et al. Differentiation of the mumps vaccine strains from the wild viruses by the nucleotide sequences of the P gene
DE69732029D1 (de) Dna enthaltende impfstoffen
JP2005532315A5 (de)
Satya et al. A pattern matching algorithm for codon optimization and CpG motif-engineering in DNA expression vectors
CN105797152A (zh) 一种疫苗组合物及其制备方法和应用
JP2002509545A (ja) Ｄｎａワクチンを伴うサブミクロン水中油型エマルジョンの使用
Webster Potential advantages of DNA immunization for influenza epidemic and pandemic planning
IL149415A0 (en) Adjuvanted genetic vaccines
HUP0200320A2 (hu) Macskaeredetű CD28-at, CD80-at, CD86-ot vagy CTL4-A-t expresszáló rekombináns vírusok és alkalmazásuk
Kebabçıoğlu et al. Next Generation Vaccines
AR041243A1 (es) Vacuna para ostertagia
AR040830A1 (es) Vacuna para combatir la infeccion que produce la mastitis
Reuter et al. Protection of mice against Friend retrovirus infection by vaccination with antigen-loaded, spleen-derived dendritic cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties